

## The dichotomous and incomplete adaptive immunity in COVID-19

Leiqiong Gao<sup>1,8</sup>, Jing Zhou<sup>1,8</sup>, Sen Yang<sup>7,8</sup>, Xiangyu Chen<sup>1</sup>, Yang Yang<sup>1</sup>, Ren Li<sup>2,3</sup>, Zhiwei Pan<sup>1</sup>, Jing Zhao<sup>6</sup>, Zhirong Li<sup>1</sup>, Qizhao Huang<sup>4</sup>, Jianfang Tang<sup>1</sup>, Li Hu<sup>1</sup>, Pinghuang Liu<sup>5</sup>, Guozhong Zhang<sup>6,\*</sup>, Yaokai Chen<sup>7,\*</sup> & Lilin Ye<sup>1,\*</sup>

<sup>1</sup>Institute of Immunology, Third Military Medical University, Chongqing 400038, China.

<sup>2</sup>State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, Heilongjiang 150001, China.

<sup>3</sup>College of Veterinary Medicine, Northeast Agricultural University, Harbin Heilongjiang, 150030, China.

<sup>4</sup>Cancer Center, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, China.

<sup>5</sup>Comparative Immunology Research Center, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China.

<sup>6</sup>Key Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China.

<sup>7</sup>Chongqing Public Health Medical Center, Chongqing 400038, China.

<sup>8</sup>These authors contributed equally to this work.

\*Corresponding authors: Guozhong Zhang ([zhanggz@cau.edu.cn](mailto:zhanggz@cau.edu.cn)), Yaokai Chen ([yaokaichen@hotmail.com](mailto:yaokaichen@hotmail.com)) and Lilin Ye ([yelilinlcmv@tmmu.edu.cn](mailto:yelilinlcmv@tmmu.edu.cn)).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 45 **Summary**

46 The adaptive immunity that protects patients from coronavirus disease 2019 (COVID-19),  
47 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is not well  
48 characterized. In particular, the asymptomatic patients have been found to induce weak and  
49 transient SARS-CoV-2 antibody responses, but the underlying mechanisms remain unknown;  
50 meanwhile, the protective immunity that guide the recovery of these asymptomatic patients is  
51 also not well studied. Here, we characterized SARS-CoV-2-specific B-cell and T-cell responses  
52 in 10 asymptomatic patients and 49 patients with other disease severity (mild, n=10, moderate,  
53 n=32, severe, n=7) and found that asymptomatic or mild symptomatic patients failed to mount  
54 virus-specific germinal center (GC) B cell responses that result in robust and long-term humoral  
55 immunity, assessed by GC response indicators including follicular helper T ( $T_{FH}$ ) cell and  
56 memory B cell responses as well as serum CXCL13 levels. Alternatively, these patients  
57 mounted potent virus-specific  $T_H1$  and  $CD8^+$  T cell responses. In sharp contrast, patients of  
58 moderate or severe disease induced vigorous virus-specific GC B cell responses and associated  
59  $T_{FH}$  responses; however, the virus-specific  $T_H1$  and  $CD8^+$  T cells were minimally induced in  
60 these patients. These results therefore uncovered the protective immunity in COVID-19 patients  
61 and revealed the strikingly dichotomous and incomplete adaptive immunity in COVID-19  
62 patients with different disease severity, providing important insights into rational design of  
63 COVID-19 vaccines.

64

65

66 **Keywords:** COVID-19 patients, SARS-CoV-2, adaptive immunity, SARS-CoV-2-  
67 specific B cells, SARS-CoV-2-specific T cells

68

69

70

71

72

73

74

75

76

77

78

## 79 **Introduction**

80 As of July 19, 2020, the ongoing pandemic of COVID-19, caused by SARS-CoV-2  
81 infection, has led to over 14 million confirmed cases and 597 thousand deaths,  
82 according to WHO issued COVID-19 Situation Report-181(WHO, 2020). Thus far, no  
83 vaccines has been approved to prevent SARS-CoV-2 infection, albeit several types of  
84 vaccine candidates reported at different clinical trial stages (Amanat and Krammer,  
85 2020; Thanh Le et al., 2020).

86

87 The SARS-CoV-2 infected patients generally manifest diverse clinical symptoms,  
88 ranging from no symptoms to critical illness, which can be further categorized into four  
89 groups, including asymptomatic, mild, moderate and severe(2020; Mizumoto et al.,  
90 2020; Raoult et al., 2020). The adaptive immunity, encompassing humoral and cellular  
91 immune responses, is a key to clear a wide variety of viral infections, rendering patients  
92 recovered from viral diseases(Aoshi et al., 2011). In SARS-CoV-2 infection, both virus-  
93 specific B-cell mediated humor immunity and T-cell mediated cellular immunity have  
94 been implicated in recovered COVID-19 patients(Cao et al., 2020; Grifoni et al., 2020;  
95 Le Bert et al., 2020; Ni et al., 2020; Woodruff et al., 2020). Notably, in asymptomatic  
96 patients, SARS-CoV-2-specific IgGs were minimally produced and poorly maintained  
97 (Ibarrondo FJ, 2020), in contrast, patients of severe disease mounted potent virus-  
98 specific IgG responses(Lee et al., 2020; Long et al., 2020; Zhang et al., 2020). However,  
99 the immune mechanisms underlying the dichotomous virus-specific IgG immune  
100 responses between asymptomatic or severe symptomatic patients are not well  
101 understood. Thus far, it also remains unknown whether virus-specific T cell immune  
102 responses are effectively induced to protect asymptomatic patients from progressing to  
103 severe disease. To characterize virus-specific B- and T- cell immune responses in  
104 recovered COVID-19 patients with different degrees of clinical symptoms will provide  
105 important insights into understanding the protective immunity for COVID-19, which  
106 will lay the foundation for rationally designing effective vaccines against SARS-CoV-  
107 2 infection.

108

## 109 **Results**

### 110 **subjects**

111 To explore the adaptive immune responses in recovered COVID-19 patients with  
112 different clinical symptoms, we organized a cohort of 59 adult patients (29 males and  
113 30 females), including asymptomatic (n=10), mild (n=10), moderate (n=32), severe  
114 (n=7) symptoms, admitted to Chongqing Public Health Center, China (Table S1&S2).  
115 All the patients were positive with SARS-CoV-2 nucleic acid testing. The clinical and  
116 pathological characteristics were summarized in Table S2. The disease severity was  
117 stratified into asymptomatic, mild, moderate and severe based on the national diagnosis  
118 and treatment guideline of COVID-19 (7<sup>th</sup> edition) in China(2020) (Table S1). The  
119 admission date was from 02/06/2020 to 04/24/2020 and the average duration of  
120 hospitalization was 19 (7-51) days. The peripheral blood mononuclear cells (PBMCs)  
121 and sera were collected at 10 to 17-day post-discharge for all the patients. For  
122 asymptomatic patients, their PBMCs were harvested twice during the hospitalization.

123

### 124 **Failure of SARS-CoV-2-specific GC B cell reaction in asymptomatic COVID-19** 125 **patients**

126 By flow cytometry analysis, we found comparable proportions of CD4<sup>+</sup>, CD8<sup>+</sup> T cells  
127 and B cells among PBMCs between patients with asymptomatic, mild illness and  
128 healthy controls. However, moderate, and severe symptomatic patients exhibited a  
129 significant reduction in proportions of CD4<sup>+</sup> and CD8<sup>+</sup> T cells but a marked increase in  
130 frequencies of B-cells compared to healthy controls (Figure. S1A-S1C), consistent with  
131 the observations in recent studies(Wen et al., 2020; Woodruff et al., 2020).

132

133 The increase of total B cell compartment in recovered COVID-19 patients of moderate  
134 and severe illness likely indicated elevated SARS-CoV2-specific B cell responses. To  
135 test this hypothesis, we investigated B cells specifically recognizing SARS-CoV-2  
136 spike protein subunits, S1 and S2, both of which represent dominant antigens of SARS-  
137 CoV-2 to induce virus-specific B-cell responses(Chen et al., 2020; Ho, 2020). As  
138 expected, we noted remarkably increased S1/S2-specific B cells in recovered patients

139 with moderate or severe symptoms compared to those in recovered patients of  
140 asymptomatic or mild illness (Figure. 1A, 1C). Coincident with these results, we also  
141 observed a substantial enhanced S1/S2-specific memory B cell population  
142 ( $\text{IgD}^{\text{low}}\text{CD19}^+\text{S1}^+/\text{S2}^+\text{CD27}^{\text{hi}}$ ) in patients with moderate (about 10% of S1/S2-specific  
143 B cells) or severe disease (about 25% of S1/S2-specific B cells), while memory B-cell  
144 fractions were scarcely shown in patients of asymptomatic or mild illness (Figure.1B,  
145 1D). In line with these results, we found S1/S2-specific IgG titers highest in sera of  
146 patients with moderate or severe disease, while lowest in sera of patients with  
147 asymptomatic or mild disease, consistent with the results observed in recent  
148 studies(Long et al., 2020) (Figure.1E, 1F).

149

150 Germinal center (GC) reaction in B-cell follicles within secondary lymphoid tissues  
151 gives rise to long-lived memory B cells and bone-marrow resident plasma cells capable  
152 of constitutively secreting antigen-specific IgGs, which strictly depends on the help  
153 provided by cognate follicular helper T ( $\text{T}_{\text{FH}}$ ) cells(Huang et al., 2019; Pedros et al.,  
154 2016). Since lymphoid tissues are inaccessible from recovered COVID-19 patients, we  
155 took advantage of measuring circulating  $\text{T}_{\text{FH}}$  ( $\text{cT}_{\text{FH}}$ ) cell and chemokine CXCL13 to  
156 reliably indicate the magnitude of ongoing GC responses(Brenna et al., 2020; McGuire  
157 et al., 2019). In support of aforementioned results, we noted a  $\text{PD1}^{\text{hi}}\text{CXCR5}^{\text{hi}}$   $\text{cT}_{\text{FH}}$   
158 population accounting for about 15% of total  $\text{CD4}^+$  T cells in COVID-19 patients  
159 recovered from severe disease, about 5% in patients of moderate disease, while such  
160 population was almost unappreciable in counterparts with asymptomatic or mild  
161 disease (Figure. 1G, 1H). Likewise, we observed the minimal CXCL13 concentration  
162 in sera from recovered patients with asymptomatic or mild illness; In stark contrast,  
163 copious CXCL13 was detected in sera from patients recovered from moderate (average  
164 415 pg/ml) or severe disease (average 850 pg/ml) (Figure. 1I). Further correlation  
165 analysis revealed the high relevance between S1/S2-specific IgG antibodies and total  
166 B-cell frequencies, CXCL13 concentration and frequencies of  $\text{cT}_{\text{FH}}$ (Figure. S2A-S2F).  
167 We also observed the high correlation between CXCL13 concentration and frequencies  
168 of  $\text{cT}_{\text{FH}}$  (Figure. S2G).

169

## 170 **Transient SARS-CoV-2-specific B cell response in asymptomatic individuals**

171 Given the failure of inducing prolonged SARS-CoV-2-specific B-cell responses by  
172 asymptomatic or mild patients, we wonder whether these patients have mounted  
173 transient virus-specific B-cell responses during their hospitalization. To this end, we  
174 first analyzed S1- or S2-specific B cell frequencies in their PBMCs at different time  
175 points during hospitalization. We found that the peak of S1/S2-specific B cell responses  
176 was induced at early stage (day 0-3) of hospitalization, which rapidly waned at the  
177 middle and convalescent stages (Figure. 2A, 2C). Concomitantly, we observed the  
178 similar dynamics of plasmablasts ( $CD19^+CD20^-CD27^{hi}CD38^{hi}$ ) (Figure.2B, 2D), which  
179 generally reflect the extrafollicular antibody responses during primary viral  
180 infection(Carter et al., 2017; Fink, 2012; Woodruff et al., 2020). In keeping with these  
181 observations, we also noticed the relatively higher S1- and S2- specific IgG titers at the  
182 middle stage (5-10 day post hospitalization) of hospitalization than those at both early  
183 (0-3 day post hospitalization) and convalescent stages (more than 10 days after COVID-  
184 19 nucleic acid test shown negative) (Figure. 2E). Furthermore, we found nearly no  
185  $cT_{FH}$  population induced and CXCL13 secreted from early phase of hospitalization to  
186 convalescent stages (Figure. 2F-2H). These data collectively revealed that SARS-CoV-  
187 2-specific B cell responses were only transiently induced in asymptomatic patients and  
188 sustained GC responses that give rise to long-term memory B cells and IgG-secreting  
189 plasma cells were likely absent in these patients, explaining the weak and short-term  
190 SARS-CoV-2 specific IgGs in these patients reported most recently (Long et al., 2020).  
191 Taken together, our results demonstrate that compared to potent and sustained SARS-  
192 CoV-2-specific GC B cell responses mounted in COVID-19 patients recovered from  
193 moderate or severe symptoms, asymptomatic or mild symptomatic COVID-19 patients  
194 only induced weak and transient SARS-CoV-2-specific B cell responses.

195

## 196 **Potent SARS-CoV-2 specific cellular immune responses in COVID-19 patients** 197 **with asymptomatic disease**

198 In addition to B-cell associated humoral immunity, the cellular immunity mediated by

199  $T_H1$  and cytotoxic  $CD8^+$  T lymphocytes also plays a critical role in the control of viral  
200 infection(Aoshi et al., 2011; Chen et al., 2005; Janice Oh et al., 2012; Mahallawi et al.,  
201 2018; Wong et al., 2004; Yoo et al., 2013). The failure in the induction of a protective  
202 humoral immunity by COVID-19 patients recovered from asymptomatic or mild  
203 disease may indicate an alternative strong cellular immunity that protected these  
204 patients from developing severe disease. To test this hypothesis, we sought to examine  
205 SARS-CoV-2-specific cellular immunity in recovered COVID-19 patients of different  
206 disease severity. To define the SARS-CoV2-specific  $CD4^+$  and  $CD8^+$  T cells, we  
207 stimulated total PBMCs with SARS-CoV-2 dominant antigen (S1, S2 and nucleoprotein,  
208 N) cocktails for 48 hours(Ni et al., 2020). After antigen stimulation, we observed the  
209 background levels of IFN- $\gamma$  producing  $CD4^+$  and  $CD8^+$  T cells in PBMCs of healthy  
210 controls; in contrast, in asymptomatic patients, the proportions of IFN- $\gamma$  producing  
211  $CD4^+$  and  $CD8^+$  T cells were substantially enhanced (Figure. 3A, 3B, 3E, 3F),  
212 indicative of the specificity of our strategy in analyzing SARS-CoV-2-specific  $CD4^+$   
213 and  $CD8^+$  T cells. Next, we compared the proportions of  $T_H1$  cells that secrete hallmark  
214 cytokine IFN- $\gamma$  in PBMCs among patients of different disease severity. Strikingly, we  
215 found the remarkably upregulated abundances of virus-specific IFN- $\gamma$ -secreting  $T_H1$   
216 cells in asymptomatic or mild symptomatic patients relative to healthy controls;  
217 however, in patients with moderate or severe symptoms, they only exhibited  
218 background levels of virus-specific IFN- $\gamma$ -producing  $T_H1$  cells post antigen stimulation  
219 as healthy control (Figure. 3A, 3B). Moreover, among those IFN- $\gamma$ -producing  $T_H1$  cells,  
220 around 10% of them were found to express cytolytic molecules granzyme B (GZMB)  
221 and perforin in patients of asymptomatic or mild illness, both of which have been found  
222 to be critical for the control of respiratory viral infection(Takeuchi and Saito, 2017),  
223 while only around 2.5% of GZMB and perforin-producing  $T_H1$  cells in patients with  
224 moderate or severe disease (Figure. 3C, 3D). These results together indicated that virus-  
225 specific  $CD4^+$  T cell responses was much biased toward to  $T_H1$  over  $T_{FH}$  cells in  
226 asymptomatic or mild symptomatic patients, while vice versa in patients with moderate  
227 or severe disease. The cellular and molecular mechanisms underlying disease severity-  
228 dependent virus-specific  $CD4^+$  T-cell differentiation in COVID-19 patients warrants



229 further investigations.

230

231 Next, we assessed SARS-CoV-2-specific CD8<sup>+</sup> T cell responses in COVID-19  
232 recovered patients. Similar to the results of virus-specific T<sub>H1</sub> responses, we found  
233 substantially induced virus-specific IFN- $\gamma$ -producing CD8<sup>+</sup> T cells in asymptomatic or  
234 mild symptomatic patients as compared to healthy controls, whereas very limited IFN- $\gamma$ -  
235 producing CD8<sup>+</sup> T cells in patients of moderate or severe symptoms (Figure. 3E, 3F).  
236 To further assess the cytolytic functionality of virus-specific CD8<sup>+</sup> T cells in COVID-  
237 19 patients, we first gated on virus-specific IFN- $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells, followed by measuring  
238 the frequencies of cells capable of producing GZMB and perforin. We found that in  
239 asymptomatic or mild symptomatic patients, approximate 60% of IFN- $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells  
240 simultaneously produced GZMB and perforin, whereas only 12% or 3% of IFN- $\gamma$ <sup>+</sup>  
241 CD8<sup>+</sup> T cells were able to make both cytolytic molecules in moderate or severe patients  
242 (Figure.3G, 3H). These data therefore revealed that albeit the failure in mounting  
243 SARS-CoV-2-specific humoral immunity, asymptomatic or mild symptomatic patients  
244 were able to induce a profound virus-specific cellular (T<sub>H1</sub> and CD8<sup>+</sup> T cell) immunity.  
245 In sharp contrast, patients of moderate or severe disease were able to generate potent  
246 SARS-CoV-2-specific humoral immunity, but they failed to induce effective virus-  
247 specific cellular immunity. The mechanisms underlying disease severity-associated  
248 dichotomous humoral and cellular immunity in COVID-19 patients need to be  
249 investigated in the future.

250

### 251 **Early induced SARS-CoV-2 specific cellular immune responses in asymptomatic** 252 **or mild individuals**

253 Given the vigorous cellular responses detected in recovered COVID-19 patients of  
254 asymptomatic or mild disease, we wonder whether these patients have induced strong  
255 good virus-specific T-cell responses at the early phase during their hospitalization. After  
256 SARS-CoV-2 antigen stimulation, we found that IFN- $\gamma$  producing CD4<sup>+</sup> and CD8<sup>+</sup> T  
257 cells was increased at early stage (day 0-3) of hospitalization in these asymptomatic  
258 patients, which were then well maintained at the middle (day 5-10) of hospitalization



259 and convalescent stages (Figure. 4A, 4B, 4E, 4F). Concomitantly, we observed the  
260 similar dynamics of frequencies of T cells capable of producing GZMB and perforin in  
261 these asymptomatic patients (Figure.4C, 4D, 4G, 4H). These data collectively revealed  
262 that SARS-CoV-2-specific  $T_H1$  and  $CD8^+$  T cell responses were rapidly induced and  
263 sustained in asymptomatic patients.

264

## 265 **Discussion**

266 Similar to most recent reports (Ibarondo FJ, 2020; Long et al., 2020), our study  
267 found that anti-SARS-CoV-2-antibodies were rapidly decay in asymptomatic or mild  
268 patients. We further found SARS-CoV-2-specific B cell responses were only transiently  
269 induced in early infection phase in asymptomatic or mild patients. In keeping with these  
270 observations, sustained GC responses that give rise to long-term memory B cells and  
271 IgG-secreting plasma cells were almost absent in these patients. These results therefore  
272 explained the phenomenon that asymptomatic patients failed to generate and maintain  
273 a long-term SARS-CoV-2-specific IgG response.

274 In contrast to humoral immunity, we found that the virus-specific  $T_H1$  and  $CD8^+$  T  
275 cell immune responses were rapidly induced and sustained in asymptomatic or mild  
276 symptomatic patients as compared to patients with moderate or severe disease, which  
277 presumably protect them from progressing to severe COVID-19. We also envision that  
278 the rapid and robust virus-specific  $T_H1$  and  $CD8^+$  T cell responses may effectively  
279 curtail the SARS-CoV-2 replication, which results in the inefficient viral antigen  
280 production and limits the GC reaction that requires sufficient antigen stimulation.  
281 Memory T cells induced by previous pathogens can protect the individual from re-  
282 infecting the similar pathogens with common epitopes and shape the clinical severity  
283 of subsequent infections (Welsh and Selin, 2002). Besides SARS-CoV-1 and MERS-  
284 CoV, there are another four virus, which are endemically transmitted and cause the  
285 common cold (OC43, HKU1, 229E and NL63) (Cui et al., 2019). Recently studies  
286 found there exists cross-reactive T cell recognition between circulating ‘common cold’  
287 coronaviruses and SARS-CoV-2(Grifoni et al., 2020; Le Bert et al., 2020). It is therefore  
288 of great interest to examine whether the history of “common cold” coronavirus

289 infection with pre-existing SARS-CoV-2 cross-reactive T cells could determine the  
290 clinically asymptomatic state in COVID-19 patients.

291 In summary, we revealed a striking dichotomous pattern of humoral and cellular  
292 immunity induced in patients of asymptomatic/mild or moderate/severe disease. The  
293 highly induced virus-specific T<sub>H</sub>1 and CD8<sup>+</sup> T cell immune responses in asymptomatic  
294 or mild symptomatic patients may protect them from progressing to severe COVID-19  
295 in the absence of humoral immunity, while potent virus-specific B cell responses likely  
296 account for the recovery of patients of moderate or severe COVID-19. These results  
297 supported the notion that SARS-CoV-2 infection generally induced paralyzed adaptive  
298 immunity, either humoral or cellular, suggesting that the induction of both optimal  
299 humoral and cellular immunity may be crucial for an effective prophylactic vaccine to  
300 prevent SARS-CoV-2 infection.

301

### 302 **Acknowledgement**

303 This work was supported by grants from the National Science and Technology Major  
304 Project (No. 2017ZX10202102-006-002 to L.Y.), the National Natural Science Fund  
305 for Distinguished Young Scholars (No. 31825011 to L.Y.), the National Key Research  
306 Development Plan (No.2016YFA0502202 to L. Ye) and the Chongqing Special  
307 Research Project for Novel Coronavirus Pneumonia Prevention and Control (No.  
308 cstc2020jscx-2 to L.Y.; No. cstc2020jscx-fyzz0074 to Y.C.; ocstc2020jscx-fyzz0135 to  
309 Y.C.).

310

### 311 **Author contributions**

312 L.G., J.Z., S.Y., X.C., Y.Y., R.L., Z.P., J.Z., Z.L., Q.H., J.T., and L.H. performed the experiments.  
313 L.Y. designed the study, analyzed the data and wrote the paper with L.G., J.Z., S.Y., P.L., G.Z.  
314 and Y.C.; and L.Y., G.Z. and Y.C. supervised the study.

315

### 316 **Conflict of interest**

317 The authors declare no competing interests.

318


## 319 Reference

- 320 (2020). COVID-19 Treatment Guidelines, 7<sup>th</sup> edition (National Health Commission of  
321 the People's Republic of China, 2020).
- 322 Amanat, F., and Krammer, F. (2020). SARS-CoV-2 Vaccines: Status Report. *Immunity* 52, 583-589.
- 323 Aoshi, T., Koyama, S., Kobiyama, K., Akira, S., and Ishii, K.J. (2011). Innate and adaptive immune  
324 responses to viral infection and vaccination. *Current opinion in virology* 1, 226-232.
- 325 Brenna, E., Davydov, A.N., Ladell, K., McLaren, J.E., Bonaiuti, P., Metsger, M., Ramsden, J.D.,  
326 Gilbert, S.C., Lambe, T., Price, D.A., *et al.* (2020). CD4(+) T Follicular Helper Cells in Human Tonsils  
327 and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4(+) Cells. *Cell reports* 30, 137-  
328 152.e135.
- 329 Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., *et al.*  
330 (2020). Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-  
331 Cell Sequencing of Convalescent Patients' B Cells. *Cell* 182, 73-84.e16.
- 332 Carter, M.J., Mitchell, R.M., Meyer Sauter, P.M., Kelly, D.F., and Trück, J. (2017). The Antibody-  
333 Secreting Cell Response to Infection: Kinetics and Clinical Applications. *Frontiers in immunology* 8,  
334 630.
- 335 Chen, H., Hou, J., Jiang, X., Ma, S., Meng, M., Wang, B., Zhang, M., Zhang, M., Tang, X., Zhang, F.,  
336 *et al.* (2005). Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS)  
337 coronavirus in recovered SARS patients and healthy individuals. *Journal of immunology* (Baltimore,  
338 Md. : 1950) 175, 591-598.
- 339 Chen, X., Li, R., Pan, Z., Qian, C., Yang, Y., You, R., Zhao, J., Liu, P., Gao, L., Li, Z., *et al.* (2020).  
340 Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin  
341 converting enzyme 2 receptor. *Cell Mol Immunol* 17, 647-649.
- 342 Cui, J., Li, F., and Shi, Z.L. (2019). Origin and evolution of pathogenic coronaviruses. *17*, 181-192.
- 343 Fink, K. (2012). Origin and Function of Circulating Plasmablasts during Acute Viral Infections.  
344 *Frontiers in immunology* 3, 78.
- 345 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings, S.A.,  
346 Sutherland, A., Premkumar, L., Jadi, R.S., *et al.* (2020). Targets of T Cell Responses to SARS-CoV-2  
347 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* 181, 1489-  
348 1501.e1415.
- 349 Ho, M. (2020). Perspectives on the development of neutralizing antibodies against SARS-CoV-2.  
350 *Antibody therapeutics* 3, 109-114.
- 351 Huang, Q., Xu, L., and Ye, L. (2019). T cell immune response within B-cell follicles. *Advances in*  
352 *immunology* 144, 155-171.
- 353 Ibarondo FJ, F.J., Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, Ferbas KG, Tobin NH,  
354 Aldrovandi GM, Yang OO (2020). Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild  
355 Covid-19. *The New England journal of medicine*.
- 356 Janice Oh, H.L., Ken-En Gan, S., Bertoletti, A., and Tan, Y.J. (2012). Understanding the T cell immune  
357 response in SARS coronavirus infection. *Emerging microbes & infections* 1, e23.
- 358 Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y., Lin, M.,  
359 Tan, N., Linster, M., *et al.* (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-19 and  
360 SARS, and uninfected controls. *Nature*.
- 361 Lee, Y.L., Liao, C.H., Liu, P.Y., Cheng, C.Y., Chung, M.Y., Liu, C.E., Chang, S.Y., and Hsueh, P.R.  
362 (2020). Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients. *The*

363 Journal of infection.  
364 Long, Q.X., Tang, X.J., Shi, Q.L., Li, Q., and Deng, H.J. (2020). Clinical and immunological  
365 assessment of asymptomatic SARS-CoV-2 infections. *Nature medicine*.  
366 Mahallawi, W.H., Khabour, O.F., Zhang, Q., Makhdoum, H.M., and Suliman, B.A. (2018). MERS-CoV  
367 infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. *Cytokine*  
368 *104*, 8-13.  
369 McGuire, H.M., Bothwell, M., Vagefi, P.A., Scully, E., Tomaras, G.D., Davis, M.M., Poignard, P.,  
370 Ahmed, R., Walker, B.D., Pulendran, B., *et al.* (2019). CXCL13 as a Biomarker of Immune Activation  
371 During Early and Chronic HIV Infection. *Proceedings of the National Academy of Sciences of the*  
372 *United States of America* *10*, 289.  
373 Mizumoto, K., Kagaya, K., Zarebski, A., and Chowell, G. (2020). Estimating the asymptomatic  
374 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship,  
375 Yokohama, Japan, 2020. *Euro surveillance : bulletin Europeen sur les maladies transmissibles =*  
376 *European communicable disease bulletin* *25*.  
377 Ni, L., Ye, F., Cheng, M.L., Feng, Y., Deng, Y.Q., Zhao, H., Wei, P., Ge, J., Gou, M., Li, X., *et al.*  
378 (2020). Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19  
379 Convalescent Individuals. *Immunity* *52*, 971-977.e973.  
380 Pedros, C., Zhang, Y., Hu, J.K., Choi, Y.S., Canonigo-Balancio, A.J., and Yates, J.R., 3rd (2016). A  
381 TRAF-like motif of the inducible costimulator ICOS controls development of germinal center TFH  
382 cells via the kinase TBK1. *Nature Immunology* *17*, 825-833.  
383 Raoult, D., Zumla, A., Locatelli, F., Ippolito, G., and Kroemer, G. (2020). Coronavirus infections:  
384 Epidemiological, clinical and immunological features and hypotheses. *Cell stress* *4*, 66-75.  
385 Takeuchi, A., and Saito, T. (2017). CD4 CTL, a Cytotoxic Subset of CD4(+) T Cells, Their  
386 Differentiation and Function. *Frontiers in immunology* *8*, 194.  
387 Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., and Mayhew,  
388 S. (2020). The COVID-19 vaccine development landscape. *Nature reviews. Drug discovery* *19*, 305-  
389 306.  
390 Welsh, R.M., and Selin, L.K. (2002). No one is naive: the significance of heterologous T-cell immunity.  
391 *Nature reviews. Immunology* *2*, 417-426.  
392 Wen, W., Su, W., Tang, H., Le, W., Zhang, X., Zheng, Y., Liu, X., Xie, L., Li, J., Ye, J., *et al.* (2020).  
393 Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. *Cell*  
394 *discovery* *6*, 31.  
395 WHO (2020). Coronavirus disease (COVID-19) Situation Report –181.  
396 Wong, C.K., Lam, C.W., Wu, A.K., Ip, W.K., Lee, N.L., Chan, I.H., Lit, L.C., Hui, D.S., Chan, M.H.,  
397 Chung, S.S., and Sung, J.J. (2004). Plasma inflammatory cytokines and chemokines in severe acute  
398 respiratory syndrome. *Clinical and experimental immunology* *136*, 95-103.  
399 Woodruff, M., Ramonell, R., Cashman, K., Nguyen, D., Ley, A., Kyu, S., Saini, A., Haddad, N., Chen,  
400 W., Howell, J.C., *et al.* (2020). Critically ill SARS-CoV-2 patients display lupus-like hallmarks of  
401 extrafollicular B cell activation. *medRxiv : the preprint server for health sciences*.  
402 Yoo, J.K., Kim, T.S., Hufford, M.M., and Braciale, T.J. (2013). Viral infection of the lung: host  
403 response and sequelae. *The Journal of allergy and clinical immunology* *132*, 1263-1276; quiz 1277.  
404 Zhang, Z., Xiao, T., Wang, Y., Yuan, J., Ye, H., Wei, L., Wang, H., Liao, X., Qian, S., Wang, Z., and  
405 Liu, L. (2020). Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers.  
406 *medRxiv : the preprint server for health sciences*.

407 **Figures and figure legends**

408 **Figure1**



410 **Figure.1 Virus-specific B cell responses to SARS-CoV2 in COVID-19 patients with**  
411 **different severity.**

412 Samples of **A**, **B** and **G** were from Healthy (#5), Asymptomatic (#7), Mild (#3),  
413 Moderate (#22), Severe (#4).

414 **A**, FACS plot examples of SARS-CoV2 S1- or S2- specific B cells (S1<sup>+</sup>/S2<sup>+</sup>CD19<sup>+</sup>) of  
415 live lymphocytes in PBMCs.

416 **B**, FACS plot examples of SARS-CoV2 S1- or S2- specific memory B cells  
417 (CD27<sup>hi</sup>IgD<sup>low</sup>), gated on S1 or S2 specific B cells (S1<sup>+</sup>/S2<sup>+</sup>CD19<sup>+</sup>) shown in **A**.

418 **C & D**, Percentages of S1 or S2 specific B cells (**C**), summarized from (**A**); and S1 or  
419 S2 specific memory B cells (**D**), summarized from (**B**), in COVID-19 recovered  
420 patients with different disease severity.

421 **E & F**, ELISA analysis of S1- and S2- specific IgG levels in convalescent-phase  
422 COVID-19 patients' sera with various groups. Dilution of 1:100 was used for serum  
423 samples.

424 **G**, FACS plot examples of cT<sub>FH</sub> (PD1<sup>hi</sup>CXCR5<sup>hi</sup>), gated on live CD4<sup>+</sup> T cells.

425 **H**, The summarization of percentages of cT<sub>FH</sub> from (**G**).

426 **I**, CXCL13 protein level in convalescent-phase COVID-19 patients' serum with various  
427 groups, measured by ELISA.

428 Bars represent the mean ± SEM. *P* values were calculated based on Bonferroni of one-  
429 way analysis. \*\*\*, *p*<0.0001, \*\*, *p*<0.001, and \*, *p*<0.05.

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449


450

451

452

453

454 **Figure 2**





456 **Figure.2 Kinetic virus-specific B cell responses to SARS-CoV2 in COVID-19**  
457 **Asymptomatic patients**

458 Sample of **A**, **B** and **F** was from Asymptomatic (#6).

459 **A & B**, FACS plot examples of SARS-CoV2 S1- or S2- specific B cells and  
460 plasmablasts (CD19<sup>+</sup>CD20<sup>-</sup>CD27<sup>hi</sup>CD38<sup>hi</sup>) cells' percentage in early phase (0-3 day  
461 post hospitalization ), acute phase (5-10 day post hospitalization), convalescent-phase,  
462 (more than 10 days after COVID-19 nucleic acid test shown negative) in the  
463 asymptomatic cohort.

464 **C & D**, Percentages of S1- or S2- specific B cells (**C**), summarized from (**B**), and  
465 plasmablasts cells (**D**), summarized from (**B**), in the asymptomatic cohort.

466 **E**, Kinetics of S1- and S2- specific IgG levels in asymptomatic patients' serum,  
467 measured by ELISA.

468 **F**, FACS plot examples of cT<sub>FH</sub> cells' percentage of asymptomatic patients.

469 **G**, Percentages of cT<sub>FH</sub>, summarized from (**O**).

470 **H**, Kinetics of CXCL13 level in asymptomatic patients' serum, measured by ELISA.

471 Bars represent the mean  $\pm$  SEM. *P* values were calculated based on Bonferroni of one-  
472 way analysis. \*\*\*, *p*<0.0001, \*\*, *p*<0.001, and \*, *p*<0.05.

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495


496

497

498

499

500 **Figure 3**



501

502 **Figure.3 SARS-CoV2 specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses in COVID-19**  
503 **convalescent patients.**

504 PBMCs of healthy control (n=8) and recovered COVID-19 patients (n=59) were  
505 stimulated with SARS-CoV-2 dominant antigen (S1, S2 and nucleoprotein, N) cocktails  
506 for 44 hours, Golgi-Plug containing Golgi-stop and DNAase were added into cell

507 culture for another 4 hours. Samples of **A**, **C**, **E** and **G** were from Healthy (#3),  
508 Asymptomatic (#4), Mild (#8), Moderate (#13), severe (#6).

509 **A**, FACS plot examples of IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> T cells in total live CD4<sup>+</sup> T cells, gated on total  
510 live CD4<sup>+</sup> T cells.

511 **B**, Bar graph shows frequency of IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> T cells in total CD4<sup>+</sup> T cells after  
512 stimulation.

513 **C**, FACS plot examples of GZMB<sup>+</sup>Perforin<sup>+</sup>CD4<sup>+</sup> T cells in total IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> T cells,  
514 gated on total live IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> T cells.

515 **D**, Frequency of GZMB<sup>+</sup>Perforin<sup>+</sup>CD4<sup>+</sup> T cells in total IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> T cells, summarized  
516 form (**C**).

517 **E**, FACS plot examples of IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells in total live CD8<sup>+</sup> T cells, gated on total  
518 live CD8<sup>+</sup> T cells.

519 **F**, Bar graph shows frequency of IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells in total CD8<sup>+</sup> T cells after  
520 stimulation.

521 **G**, FACS plot examples of GZMB<sup>+</sup>Perforin<sup>+</sup>CD8<sup>+</sup> T cells in total IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells,  
522 gated on total live IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells.

523 **H**, Frequency of GZMB<sup>+</sup>Perforin<sup>+</sup>CD8<sup>+</sup> T cells in total IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells, summarized  
524 form (**G**).

525 Bars represent the mean  $\pm$  SEM. *P* values were calculated based on Bonferroni of one-  
526 way analysis. \*\*\*, *p*<0.0001, \*\*, *p*<0.001, and \*, *p*<0.05.

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546


547

548

549

550

551 **Figure 4**



552

553 **Figure.4 Kinetic SARS-CoV2 specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses in COVID-**  
554 **19 asymptomatic patients.**

555 PBMCs of healthy control (n=8) and asymptomatic COVID-19 patients (n=10) were  
556 stimulated with SARS-CoV-2 dominant antigen (S1, S2 and nucleoprotein, N) cocktails  
557 for 44 hours, Golgi-Plug containing Golgi-stop and DNAase were added into cell  
558 culture for another 4 hours. Representative samples were from Healthy (#3),  
559 Asymptomatic (#3).

560 **A**, FACS plot examples of IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> T cells in total live CD4<sup>+</sup> T cells, gated on total  
561 live CD4<sup>+</sup> T cells.

562 **B**, Bar graph shows frequency of IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> T cells in total CD4<sup>+</sup> T cells after  
563 stimulation.

564 **C**, FACS plot examples of GZMB<sup>+</sup>Perforin<sup>+</sup>CD4<sup>+</sup> T cells in total IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> T cells,  
565 gated on total live IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> T cells.

566 **D**, Frequency of GZMB<sup>+</sup>Perforin<sup>+</sup>CD4<sup>+</sup> T cells in total IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> T cells, summarized  
567 form (**C**).

568 **E**, FACS plot examples of IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells in total live CD8<sup>+</sup> T cells, gated on total  
569 live CD8<sup>+</sup> T cells.

570 **F**, Bar graph shows frequency of IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells in total CD8<sup>+</sup> T cells after  
571 stimulation.

572 **G**, FACS plot examples of GZMB<sup>+</sup>Perforin<sup>+</sup>CD8<sup>+</sup> T cells in total IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells,  
573 gated on total live IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells.

574 **H**, Frequency of GZMB<sup>+</sup>Perforin<sup>+</sup>CD8<sup>+</sup> T cells in total IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells, summarized  
575 form (**G**).

576 Bars represent the mean  $\pm$  SEM. *P* values were calculated based on Bonferroni of one-  
577 way analysis. There was no statistically significant difference among different stage of  
578 asymptomatic patients.

579

580

581

582

583

584

585

586

587

588

589

590

## 591 **Material and Methods**

### 592 **Human subjects**

593 Blood samples from 8 healthy adult donors were obtained by the Institute of  
594 Immunology of Army Medical University, which has no contact with SARS-CoV-2 and  
595 test negative for SARS-CoV-2 RNA. These donors had no known history of any  
596 significant systemic diseases, including but not limited to, for example, autoimmune  
597 disease, kidney or liver disease, congestive heart failure, malignancy, coagulopathy,  
598 hepatitis B or C, or HIV infection.

599 The 59 COVID-19 convalescent donors enrolled in the study were provided written  
600 informed consent. The blood samples of COVID-19 patients were obtained from  
601 Chongqing Public Health Medical Center. The study received IRB approvals at  
602 Chongqing Public Health Medical Center (2020-023-01-KY).

603

### 604 **SARS-CoV-2 S1, S2 ELISA**

605 ELISA protocol generally followed that of precious study(Chen et al., 2020). Briefly,  
606 costar 96-well clear plates (Costar, 42592) were coated with 500ng/mL SARS-CoV-2  
607 S1 protein (Sino Biological, 40591-V08H) or SARS-CoV-2 S2 protein (Sino Biological,  
608 40590-V08B) overnight at 4°C. The next day, plates were blocked with 100 µL blocking  
609 buffer (5% FBS and 0.1% Tween 20 in PBS) at room temperature for 2 hours. After  
610 washing with PBST buffer (0.1% Tween 20 in PBS), 1:100 diluted serum was then  
611 added to the plates and incubated for 1 hour at room temperature. Serum was diluted in  
612 blocking buffer. Serum was heat inactivated at 56°C for 30 minutes before added to the  
613 plate. Then, these plates were washed 5 times with 0.05% PBS-Tween 20. Then these  
614 ELISA plates were incubated with anti-human IgG HRP antibody (Bioss Biotech,  
615 0297D) at room temperature for 1 hour. Anti-human IgG antibody was used at a 1:3000  
616 dilution. Then, these plates were washed 5 times with 0.05% PBS-Tween 20 and 100  
617 µL TMB buffer (Beyotime, P0209) was added and reacted for 15 minutes at room  
618 temperature. These reactions were stopped with 1M H<sub>2</sub>SO<sub>4</sub> stopping buffer. Plates were  
619 read on a Beckman Coulter Plate Reader at 450 nm, and ODs were background  
620 subtracted.

621

## 622 **CXCL13 ELISA**

623 The costar 96-well clear plates (Costar, 42592) were coated with 2µg/mL CXCL13  
624 monoclonal antibody (Sino Biological, 70057-MM13) overnight at 4°C. The next day,  
625 plates were blocked with 100 µL blocking buffer (5% FBS and 0.1% Tween 20 in PBS)  
626 at room temperature for 2 hours. After washing with PBST buffer (0.1% Tween 20 in  
627 PBS), heat-inactivation serum was then added to the plates and incubated for 2 hours  
628 at room temperature. Then, these plates were washed 5 times with 0.05% PBS-Tween  
629 20. Then these ELISA plates were incubated with 2µg/mL CXCL13 polyclonal  
630 antibody (Sino Biological, 70057-RP01) for 2 hours at room temperature. These plates  
631 were washed 5 times with 0.05% PBS-Tween 20. Then incubated with goat anti-rabbit  
632 IgG HRP antibody (Sigma) at room temperature for 1 hour. Anti-rabbit IgG antibody  
633 was used at a 1:3000 dilution. Then, these plates were washed 5 times with 0.05% PBS-  
634 Tween 20 and 100 µL TMB buffer (Beyotime, P0209) was added and reacted for 15  
635 minutes at room temperature. These reactions were stopped with 1M H<sub>2</sub>SO<sub>4</sub> stopping  
636 buffer. Plates were read on a Beckman Coulter Plate Reader at 450 nm, and ODs were  
637 background subtracted.

638

## 639 **PBMC isolation and serum collection**

640 Whole blood in micro-anticoagulant tube was centrifuged for 15 min at 2200 rpm at  
641 room temperature to separate the cellular fraction. Peripheral blood mononuclear cells  
642 (PBMCs) were isolated by density-gradient sedimentation using Ficoll-Paque  
643 (Haoyang Biological, Tianjin, China). Briefly speaking, blood 1:1 diluted with PBS,  
644 was gently layered over an equal volume of Ficoll in a 15 ml BD centrifuge tube and  
645 centrifuged for 25 minutes at 2200rpm without brake. There were four layers, the  
646 second layer contained PBMCs. These cells could be gently removed using a Pasteur  
647 pipette and added to PBS to wash off any remaining platelets. Isolated PBMCs were  
648 cryopreserved in cell recovery media (90% heat inactivated fetal bovine serum and 10%  
649 DMSO, Gibco) and stored in liquid nitrogen until used in the assays. The serum was  
650 carefully removed from blood without sodium citrate treatment and stored at -80°C.



651

### 652 **SARS-CoV2 recombinant protein S1/S2 biotinylation**

653 For biotinylation, SARS-CoV2 recombinant protein S1/S2 added to a final  
654 concentration of 150 ng/ $\mu$ L, Biotin was added to 50  $\mu$ M. After fully mixed, the reaction  
655 was proceeded on ice for 2 h. Biotinylaed proteins were desalted using Zeba™ Spin  
656 Desalting Columns 7K MWCO (Cat#89882, Thermo Fisher) according to the  
657 manufacturer's instruction. Then we confirmed the biotinylation of S1/S2 using dot  
658 blotting assay.

659

### 660 **Surface staining and Flow Cytometry**

661 Cryopreserved PBMCs were thawed and rested in 10 ml complete RPMI 1640 with 10%  
662 human AB serum (Gemini Bioproducts) at 37 °C for 3 h. PBMCs were washed with  
663 FACS buffer (PBS plus 2% FBS, Gibco), and then Fc blocking reagent (Meltanyi  
664 Biotec) was added for 15 min at room temperature, followed by three time wash with  
665 FACS buffer. Cells were then incubated for 30 min on ice with corresponding antibodies  
666 or Biotinylaed S1/S2 proteins. Antibodies used in the T cell and B cells surface marker  
667 staining are listed in Table S5 and S6. Then washed three times with FACs and acquired  
668 by FACS Verse (BD Biosciences, San Jose, CA). Data were analyzed by FlowJo  
669 software (Version 10.0.8, Tree Star Inc., Ashland).

670

### 671 **Intracellular cytokine staining and Flow Cytometry**

672 PBMCs in wells of a 96-well plate with 100  $\mu$ L complete RPMI 1640 and 10% human  
673 AB serum (Gemini Bioproducts) and Pen-Strep, were incubated 44 hours with 1 $\mu$ M of  
674 recombinant proteins (S1, S2 and nucleoprotein, N). Golgi-Plug containing Golgi-stop  
675 (BD Biosciences, San Diego, CA) and DNAase (Sigma, USA) with or without 1 $\mu$ g/mL  
676 Ionomycin plus 50ng/mL phorbol 12-myristate 13-acetate (PMA) were added another  
677 4 hours into the culture. A stimulation with an equal amount of PBS was used as  
678 negative control. PMA plus ionomycin were included as positive controls. Cells were  
679 then washed with FACS buffer and surface stained for 30 minutes on ice, then fixed  
680 and permeabilized with BD Cytotfix/Cytoperm solution (BD, Cat#554722) for 30 min

681 at 4°C, followed by washing with perm/wash buffer (BD) and intracellular stained for  
682 30 minutes on ice. Antibodies used in this assay were listed in Table S7. The gates  
683 applied for the identification of Perforin, GZMB and IFN $\gamma$  positive cells were defined  
684 according the cells cultured with PBS for each sample. All samples were acquired on a  
685 BD FACSymphony cell sorter (BD Biosciences, San Diego, CA).

686

### 687 **Quantification and Statistical analysis**

688 FlowJo 10 and GraphPad Prism 8.0.2 are used for data and statistical analyses. The  
689 statistical detail information of the experiments was provided in the respective  
690 Figure legends. Correlation analyses were performed using Spearman and Mann-  
691 Whitney tests were applied for unpaired comparisons. One-way analysis was performed  
692 for more than two-group analysis. *P* values less than 0.05 were considered to be  
693 significantly statistically.

694

695

696

697

698

699

700

701

702

703

704

705

706

707


708

709

710

711 **Supplementary**

712 **Figure. S1.**



713 **Figure. S1, Frequency of B cells, CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells in total live PBMCs**  
 714 **in COVID-19 patients with different severity.**

715 Samples of **a** and **b** were from Healthy (#5), Asymptomatic (#7), Mild (#3), Moderate  
 716 (#22), severe (#4).


717 **a, b**, Representative flow cytometry plots of CD4<sup>+</sup> and CD8<sup>+</sup> T cells (**a**) and B cells (**b**)  
 718 in total live PBMCs in convalescent-phase COVID-19 patients.

719 **c**, Percentages of CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells and B cells, summarized from (**a, b**), in  
 720 COVID-19 recovered patients with different disease severity.

721 Bars represent the mean ± SEM. *P* values were calculated based on Bonferroni of one-  
 722 way analysis. \*\*\*, *p*<0.001, and \*\*, *p*<0.01.

723  
 724  
 725  
 726  
 727  
 728  
 729  
 730  
 731

732 **Figure. S2.**



733

734 **Figure. S2, Correlations between B cells frequency, serum CXCL13 concentration,**

735 **cT<sub>FH</sub> cells frequency and S1- or S2- specific IgG levels.**

736 **a, b**, Correlations between B cells frequency and S1- (**a**) or S2- (**b**) specific IgG levels.

737 **c, d**, Correlations between serum CXCL13 concentration and S1- (**c**) or S2- (**d**) specific  
738 IgG levels.

739 **e-f**, Correlations between cT<sub>FH</sub> cells frequency and S1- (**e**) or S2- (**f**) specific IgG levels.

740 **g**, Correlations between cT<sub>FH</sub> cells frequency and serum CXCL13 concentration.

741 Statistical comparisons were performed using Spearman correlation analysis.

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

**Table S1. Characteristics of patients in this study**

781

	All (n=67)	Healthy (n=8)	Asymptomatic (n=10)	Mild (n=10)	Moderate (n=32)	Severe (n=7)
<b>Age (years, median, IOQ)</b>	67 (19-74)	30.5 (25-38)	21 (19-56)	30 (19-56)	39.5 (20-67)	65 (43-74)
<b>Gender</b>						
<b>Female</b>	34	4	4	6	17	3
<b>Male</b>	33	4	6	4	15	4
<b>Onset of discharge to sample collection (days, median, IOQ)</b>	14 (10-17)		13.5 (10-15)	13.5 (10-14)	13.5 (10-16)	14 (14-17)
<b>Duration of hospitalization</b>	19 (7-51)		24 (12-51)	22 (12-31)	16.5 (7-29)	20 (13-24)

782

1. Continuous variables were shown as the median (interquartile range, IQR).

783

2. All of 59 COVID-19 patients were tested positive qPCR for SARS-CoV-2 virus RNA upon hospital admission. Patients were diagnosed as severe when meeting any one of the following conditions: 1) anhelation ( $RR \geq 30/\text{min}$ ), 2)  $SpO_2 \leq 93\%$ , 3)  $PaO_2/FiO_2 \leq 300$  mmHg and 4) imageological diagnosis of significant progress ( $> 50\%$ ) in 24-48 hours. The moderate patients were diagnosed with respiratory symptoms, fever and imageological evidence of pneumonia.

784

785

786

787

788

The mild patients were diagnosed with mild clinical symptoms and no imageological evidence of pneumonia. The asymptomatic patients were those without any clinical symptoms.

789

790

791

792

793

794

795

796

**Table S2. Characteristics of individual patients in this study**

	<b>Donors</b>	<b>Age range</b>	<b>Gender</b>	<b>Duration of hospitalization (days)</b>	<b>Onset of discharge to sample collection (days)</b>
<b>Healthy</b>	<b>#1</b>	In his 30s	Male		
	<b>#2</b>	In his 30s	Male		
	<b>#3</b>	In his 20s	Male		
	<b>#4</b>	In his 20s	Male		
	<b>#5</b>	In her 20s	Female		
	<b>#6</b>	In her 30s	Female		
	<b>#7</b>	In her 30s	Female		
	<b>#8</b>	In her 20s	Female		
<b>Asymptomatic</b>	<b>#1</b>	In his 10s	Male	27	11
	<b>#2</b>	In her 20s	Female	12	12
	<b>#3</b>	In his 20s	Male	20	14
	<b>#4</b>	In her 20s	Female	24	15
	<b>#5</b>	In his 10s	Male	39	10
	<b>#6</b>	In her 20s	Female	30	14
	<b>#7</b>	In his 20s	Male	24	14
	<b>#8</b>	In his 40s	Male	51	14
	<b>#9</b>	In her 20s	Female	23	13
	<b>#10</b>	In his 10s	Male	20	12
<b>Mild</b>	<b>#1</b>	In his 10s	Male	27	10
	<b>#2</b>	In her 20s	Female	26	11
	<b>#3</b>	In her 20s	Female	31	11
	<b>#4</b>	In her 20s	Female	16	13
	<b>#5</b>	In her 30s	Female	20	14
	<b>#6</b>	In her 50s	Female	28	14
	<b>#7</b>	In his 20s	Male	13	12
	<b>#8</b>	In his 30s	Male	12	14
	<b>#9</b>	In her 40s	Female	24	14
	<b>#10</b>	In his 30s	Male	18	14
<b>Moderate</b>	<b>#1</b>	In his 30s	Male	10	14
	<b>#2</b>	In her 50s	Female	9	14
	<b>#3</b>	In his 60s	Male	10	14
	<b>#4</b>	In his 30s	Male	12	14
	<b>#5</b>	In her 50s	Female	16	14
	<b>#6</b>	In her 40s	Female	21	10
	<b>#7</b>	In her 40s	Female	24	14



	<b>#8</b>	In her 40s	Female	29	14 <sup>797</sup>
	<b>#9</b>	In her 30s	Female	14	12
	<b>#10</b>	In her 60s	Female	18	12 <sup>798</sup>
	<b>#11</b>	In his 60s	Male	19	11 <sup>799</sup>
	<b>#12</b>	In her 60s	Female	17	13
	<b>#13</b>	In her 60s	Female	10	14 <sup>800</sup>
	<b>#14</b>	In her 20s	Female	11	12 <sup>801</sup>
	<b>#15</b>	In his 40s	Male	8	10
	<b>#16</b>	In his 30s	Male	11	10 <sup>802</sup>
	<b>#17</b>	In her 50s	Female	24	12 <sup>803</sup>
	<b>#18</b>	In her 60s	Female	20	11
	<b>#19</b>	In his 30s	Male	13	12 <sup>804</sup>
	<b>#20</b>	In her 30s	Female	25	14
	<b>#21</b>	In her 40s	Female	15	14 <sup>805</sup>
	<b>#22</b>	In his 20s	Male	18	14
	<b>#23</b>	In his 20s	Male	9	14 <sup>806</sup>
	<b>#24</b>	In her 20s	Female	27	14
	<b>#25</b>	In his 50s	Male	19	14 <sup>807</sup>
	<b>#26</b>	In his 60s	Male	13	13
	<b>#27</b>	In his 30s	Male	7	10 <sup>808</sup>
	<b>#28</b>	In his 30s	Male	18	11
	<b>#29</b>	In his 30s	Male	26	10 <sup>809</sup>
	<b>#30</b>	In his 30s	Male	10	14
	<b>#31</b>	In her 30s	Female	27	13 <sup>810</sup>
	<b>#32</b>	In her 60s	Female	17	16
<b>Severe</b>	<b>#1</b>	In his 70s	Male	29	17 <sup>811</sup>
	<b>#2</b>	In her 60s	Female	34	16
	<b>#3</b>	In her 70s	Female	16	14 <sup>812</sup>
	<b>#4</b>	In his 60s	Male	27	14
	<b>#5</b>	In his 50s	Male	20	14 <sup>813</sup>
	<b>#6</b>	In his 60s	Male	13	14
	<b>#7</b>	In her 40s	Female	17	14 <sup>814</sup>

815

816

817

818

819

820

821

**Table S3. Summary of *P* values in Figure 1-4**

822

**1. *P* values of Figure 1c**

	Healthy	Asymptomatic	Mild	Moderate	Severe
Healthy	/	*	**	***	***
Asymptomatic	/	/	*	***	***
Mild	/	/	/	**	***
Moderate	/	/	/	/	**

823

**2. *P* values of Figure 1d**

	Healthy	Asymptomatic	Mild	Moderate	Severe
Healthy	/	ns (>0.99)	ns (>0.99)	***	***
Asymptomatic	/	/	ns (>0.99)	***	***
Mild	/	/	/	***	***
Moderate	/	/	/	/	**

824

**3. *P* values of Figure 1e**

	Healthy	Asymptomatic	Mild	Moderate	Severe
Healthy	/	ns (>0.99)	ns (0.37)	***	***
Asymptomatic	/	/	ns (>0.99)	***	***
Mild	/	/	/	**	***
Moderate	/	/	/	/	**

825

**4. *P* values of Figure 1f**

	Healthy	Asymptomatic	Mild	Moderate	Severe
Healthy	/	ns (>0.99)	ns (>0.99)	***	***
Asymptomatic	/	/	ns (>0.99)	***	***
Mild	/	/	/	**	***
Moderate	/	/	/	/	***

826

**5. *P* values of Figure 1h**

	Healthy	Asymptomatic	Mild	Moderate	Severe
Healthy	/	ns (>0.99)	ns (>0.99)	***	***
Asymptomatic	/	/	ns (>0.99)	**	***
Mild	/	/	/	**	***
Moderate	/	/	/	/	***

827

**6. *P* values of Figure 1i**

	Healthy	Asymptomatic	Mild	Moderate	Severe
Healthy	/	ns (>0.99)	ns (0.28)	**	***
Asymptomatic	/	/	ns (0.71)	**	***
Mild	/	/	/	*	**
Moderate	/	/	/	/	*

828

**7. *P* values of Figure 2c**

	Healthy	Early	Middle	Convalescence
Healthy	/	***	***	*
Early	/	/	ns (0.24)	*
Middle	/	/	/	ns (0.051)

829 **8. P values of Figure 2d**

	Healthy	Early	Middle	Convalescence
Healthy	/	***	***	ns (>0.99)
Early	/	/	ns (0.07)	**
Middle	/	/	/	*

830 **9. P values of Figure 2e**

831 **S1**

	Healthy	Early	Middle	Convalescence
Healthy	/	ns (0.41)	*	ns (>0.99)
Early	/	/	ns (>0.99)	ns (0.73)
Middle	/	/	/	*

832 **S2**

	Healthy	Early	Middle	Convalescence
Healthy	/	**	***	ns (>0.99)
Early	/	/	ns (0.07)	ns (0.052)
Middle	/	/	/	**

833 **10. P values of Figure 2g**

	Healthy	Early	Middle	Convalescence
Healthy	/	*	*	ns (>0.99)
Early	/	/	ns (>0.99)	ns (0.053)
Middle	/	/	/	ns (0.11)

834 **11. P values of Figure 2h**

	Healthy	Early	Middle	Convalescence
Healthy	/	*	*	ns (>0.99)
Early	/	/	ns (0.67)	ns (0.22)
Middle	/	/	/	ns (>0.99)

835 **12. P values of Figure 3b.**

	Healthy	Asymptomatic	Mild	Moderate	Severe
Healthy	/	***	***	*	ns (0.57)
Asymptomatic	/	/	ns (>0.99)	***	***
Mild	/	/	/	**	***
Moderate	/	/	/	/	ns (>0.99)

836 **13. P values of Figure 3d.**

	Healthy	Asymptomatic	Mild	Moderate	Severe
Healthy	/	***	***	ns (>0.99)	ns (>0.99)
Asymptomatic	/	/	ns (>0.99)	***	***
Mild	/	/	/	***	***
Moderate	/	/	/	/	ns (>0.99)

837 **14. P values of Figure 3f.**

	Healthy	Asymptomatic	Mild	Moderate	Severe
Healthy	/	***	***	**	ns (0.74)
Asymptomatic	/	/	ns (>0.99)	**	***
Mild	/	/	/	**	***

Moderate	/	/	/	/	ns (0.96)
----------	---	---	---	---	-----------

838 **15. P values of Figure 3h.**

	Healthy	Asymptomatic	Mild	Moderate	Severe
Healthy	/	***	***	*	ns (>0.99)
Asymptomatic	/	/	ns (>0.99)	***	***
Mild	/	/	/	***	***
Moderate	/	/	/	/	ns (0.65)

839 **16. P values of Figure 4b.**

	Healthy	Early	Middle	Convalescence
Healthy	/	***	***	***
Early	/	/	ns (>0.99)	ns (>0.99)
Middle	/	/	/	ns (>0.99)

840 **17. P values of Figure 4d.**

	Healthy	Early	Middle	Convalescence
Healthy	/	***	***	***
Early	/	/	ns (>0.99)	ns (>0.99)
Middle	/	/	/	ns (>0.99)

841 **18. P values of Figure 4f.**

	Healthy	Early	Middle	Convalescence
Healthy	/	***	***	***
Early	/	/	ns (>0.99)	ns (>0.99)
Middle	/	/	/	ns (>0.99)

842 **19. P values of Figure 4h.**

	Healthy	Early	Middle	Convalescence
Healthy	/	***	***	***
Early	/	/	ns (>0.99)	ns (>0.99)
Middle	/	/	/	ns (>0.99)

843 P values were calculated based on Bonferroni of one-way analysis. \*\*\*,  $p < 0.0001$ , \*\*,  $p < 0.001$ , and \*,  $p < 0.05$ .

845

846

847

848

849

850

851

852

853 **Table S4 Flow cytometry antibodies in this study**

Antigen	Fluorochrome	Clone	Manufacturer	Volume/test (μL)
CD8	FITC	RPA-T8	Biolegend	0.125
PD1	PE	EH12.2H7	Biolegend	0.5
CXCR5			BD	1
Biotin			BD	0.25
Avidin	PE-Cy7		Biolegend	0.125
CD45RA	APC	HI100	Biolegend	0.125
LIVE/DEAD	APC-Cy7		Thermo fisher	0.25
CD19	APC-Cy7	H1B19	Biolegend	0.125
CD4	BV510	OKT4	Biolegend	0.125
CD20	FITC	2H7	Biolegend	0.125
CD27	PE	M-T271	Biolegend	0.5
CD19	PerCP	H1B19	BD	1
S1+S2			Sino Biological	1
Avidin	PE-Cy7		Biolegend	0.125
LIVE/DEAD	APC-Cy7		Thermo fisher	0.25
IgD	BV510	IA6-2	Biolegend	0.125
TNFα	FITC	MAb11	Biolegend	0.5
Perforin	PE	B-D48	Biolegend	0.5
CD8	PerCP	RPA-T8	Biolegend	0.125
GZMB	APC	GB11	Biolegend	0.5
LIVE/DEAD	APC-Cy7		Thermo fisher	0.25
IFNγ	BV421	4S. B3	Biolegend	0.5
CD4	BV510	OKT4	Biolegend	0.125

854

855